Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

other HCV protease inhibitor in development. In an initial Phase 1 study of ITMN-191 co-administered with low dose ritonavir in healthy volunteers, important PK parameters showed marked improvement. Clearance of the compound was dramatically reduced, resulting in significant increases in AUC and drug concentrations at later times. There were no remarkable safety findings. The potential product and patient benefits of the ritonavir boosting strategy are less frequent administration and a lower dose or pill burden for ITMN-191, which may enhance the possibility of co-formulating ITMN-191 with other direct antiviral agents.
  • At the Annual Meeting of the European Association for the Study of the Liver (EASL) in late April, results were reported from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys and ribavirin.
    • After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively.
    • There was no evidence of viral rebound during ITMN-191 treatment in any cohort.
    • ITMN-191 plus standard-of-care therapy was safe and generally well tolerated.
  • Also at the EASL meeting in late April, InterMune, Roche and Pharmasset, Inc. reported initial results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128, but no interferon or ribavirin, in patients with HCV infection. Data from the first four dosage cohorts of the study demonstrated that the combination resulted in sustained viral load reductions over the dosing period in all cohorts. The combination was well tolerated over 14 days, with no treatment-related serious adverse events (SAEs), dose reductions or discontinuations. There were no drug-drug interactions between the
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    (Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
    (Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the nation’s ... Pharm.D. to the newly created position of Vice President ... Dr. Maroulis will continue to manage the entire specialty ... pharmacies as the company expands. Dr. Maroulis has been ... has served in many different capacities in the pharmacy, ...
    (Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
    Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
    ... Mass.--A mat of nanowires with the touch and feel of paper ... and other organic pollutants, MIT researchers and colleagues report in the ... they have created a membrane that can absorb up to 20 ... for future use. The oil itself can also be recovered. Some ...
    ... Holliday Updates Investors on Growth Opportunities, NEW ... today, DuPont Chairman and CEO Charles O. Holliday, ... innovation that addresses,global macro trends related to food, ... a market-driven science company," Holliday said at the,Sanford ...
    ... By Improving the Accuracy of Tumor Grading, MapQuant Dx(TM) Genomic ... Chemotherapy Treatments per Year ... 2008 - booth 23128, CHICAGO, May 30 Ipsogen ... that markets molecular diagnostic assays,for leukaemia announced today that it ...
    Cached Biology Technology:MIT develops a 'paper towel' for oil spills 2DuPont Well Positioned for Long-Term Growth in Agricultural Productivity, Safety and Security, Renewable Energy 2DuPont Well Positioned for Long-Term Growth in Agricultural Productivity, Safety and Security, Renewable Energy 3Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy 2Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy 3Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy 4
    (Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
    (Date:12/10/2014)... 2014 You,ve been here before: you desperately need ... your password, site key or the answer to your secret ... teacher? Today, Hoyos Labs , a ... will finally put an end to the frustration that comes ... . 1U leverages a user,s smartphone to acquire his or ...
    (Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
    Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
    ... and accumulating calcium carbonate, and this is essential for ... An international research team has discovered that the amount ... is now significantly below rates measured over recent geological ... 70% lower. Coral reefs form some of ...
    ... end of the last Ice Age, trees have had thousands ... will forests adapt to the rapid pace of current climate ... grant to Drs. Stephen Keller, Andrew Elmore, Matthew Fitzpatrick, David ... for Environmental Science,s Appalachian Laboratory to study climate adaptation in ...
    ... observational technique have determined the precise configuration of humulones, ... flavor. That might not sound like a big ... results reported in scientific literature in the last 40 ... diabetes, some types of cancer and other maladies. ...
    Cached Biology News:New evidence highlights threat to Caribbean coral reef growth 2New evidence highlights threat to Caribbean coral reef growth 3New study will predict how trees will adapt to rapid climate change 2Beer's bitter compounds could help brew new medicines 2
    MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
    MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
    MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
    ... Purification Kit is designed to purify double-stranded DNA ... synthesis and PCR. The process is simple and ... 3 g can be efficiently purified and concentrated. ... DNA is bound to the Microfilter Cartridge in ...
    Biology Products: